A dynamic combination of the best in science and health technology is filling unmet needs with more precise and effective treatments.
Science isn’t just in petri dishes anymore. Novel technology is increasingly involved. Discoveries are being made and tested in the cloud. Artificial intelligence and machine learning algorithms are digesting data lakes and helping drive new discoveries, speed development and provide smarter care.
Scientific innovation capabilities drive the biopharma sector both to develop treatments and manage global health. But science has changed—so how we innovate must also change. The way we measure benefits for patients and populations is going to shape the future.
In 2019, Accenture identified and defined New Science: a dynamic combination of the best in science and health technology that is driving more growth than originally predicted.
New Science is Accenture’s global analysis of regulated scientific treatments in both the pipeline and the market. It classifies science using different dimensions to understand its dynamics for patients, companies and markets. The dimensions include:
Enables better understand of future areas of growth in disease and overall therapeutic areas, and better manage portfolio risk.
Measuring treatments that qualify as achieving current unmet need ensures development of medicines for patient impact.
Measuring medicines that coexist with technology in the near-term and future ensures a better understanding of science’s growing dependence on tech.
Scott Howell, Chief Strategy Officer, US Pharmaceuticals at Novartis and Ray Pressburger, Accenture Life Sciences Commercial Services Lead, come together to discuss recent pricing, access and affordability pressures, the realities of how the industry operates today, what they think is coming next and what it will mean for patients, providers and manufacturers.
Scott Howell and Ray Pressburger discuss ways to improve economic sustainability and unlock better access to care for the patients who truly need it.View Transcript
When a global pandemic forced the industry into unprecedented action, the global scientific community collaborated in exceptional ways and public-private partnerships drove innovation to address a common need with two highlights standing out: technology and science.
But, how can we use the lessons of COVID-19 to help us address system and patient-level affordability issues, while still advancing the discovery, development and delivery of new treatments for all health conditions?
Our research found three ways New Science can support and deliver the innovation that today’s economics demand.
"The investment in scientific innovation is born by all stakeholders and felt most deeply by patients. Now the goal must be maximizing return on that investment for patients, too. There are better, faster ways to deliver innovation—2020 proved that."
Digital Thread for Life Sciences (DTLS) is a powerful combination of product, process and quality data. Learn how.